{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06263673",
            "orgStudyIdInfo": {
                "id": "23-008183"
            },
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Anti-Diabetic Medications to Fight PD and LBD",
            "officialTitle": "Anti-Diabetic Medications to Fight Parkinson's Disease and Lewy Body Dementia",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "anti-diabetic-medications-to-fight-pd-and-lbd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-09",
            "studyFirstSubmitQcDate": "2024-02-09",
            "studyFirstPostDateStruct": {
                "date": "2024-02-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jessica R. Wilson",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia."
        },
        "conditionsModule": {
            "conditions": [
                "Lewy Body Dementia",
                "Parkinson Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Sitagliptin Group",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects will receive sitagliptin for the approximately 4-week treatment period.",
                    "interventionNames": [
                        "Drug: Sitagliptin"
                    ]
                },
                {
                    "label": "Dapagliflozin Group",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects will receive dapagliflozin for the approximately 4-week treatment period.",
                    "interventionNames": [
                        "Drug: Dapagliflozin"
                    ]
                },
                {
                    "label": "Placebo Group",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Subjects will receive placebo for the approximately 4-week treatment period.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Sitagliptin",
                    "description": "100 mg once daily, oral",
                    "armGroupLabels": [
                        "Sitagliptin Group"
                    ],
                    "otherNames": [
                        "DPP4 inhibitor therapy"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Dapagliflozin",
                    "description": "10 mg once daily, oral",
                    "armGroupLabels": [
                        "Dapagliflozin Group"
                    ],
                    "otherNames": [
                        "SGLT2 inhibitor therapy"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.",
                    "armGroupLabels": [
                        "Placebo Group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS)",
                    "description": "Measures various aspects of Parkinson's disease. Score ranges from 0 to 260, with 0 indicating no disability and 260 indicating total disability.",
                    "timeFrame": "Baseline, 4 weeks"
                },
                {
                    "measure": "Change in Mini Mental State Examination",
                    "description": "Set of 11 questions used by clinicians to check for cognitive impairment. Scoring 30-25 indicates normal and below 24 is abnormal indicating possible cognitive impairment",
                    "timeFrame": "Baseline, 4 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Glucose",
                    "description": "fasting",
                    "timeFrame": "Baseline, 4 weeks"
                },
                {
                    "measure": "Supine blood pressure",
                    "description": "Resting average for a least 10 minutes of three blood pressures collected by an automated oscillometric device (blood pressure cuff) reported in mm Hg",
                    "timeFrame": "Baseline, 4 weeks"
                },
                {
                    "measure": "Standing blood pressure",
                    "description": "Standing average for 15 minutes of three blood pressures collected by an automated oscillometric device (blood pressure cuff) reported in mm Hg",
                    "timeFrame": "Baseline, 4 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Parkinson's disease or Lewy Body Dementia (diagnosis confirmed by neurologist at Mayo Clinic) with stable neurological treatment in the past approximately three months.\n* Glucose intolerance or mild diabetes: The American Diabetes Association criteria for pre-diabetes/ glucose intolerance includes fasting glucose 100-125, random glucose 140-199, or hemoglobin A1C 5.7-6.4% and diabetes is \\> 125 mg/dL, \\> 200 mg/dL, and 6.5% or greater, respectively (40). It has been previously reported that 50-80% of individuals with Parkinson's disease have abnormal glucose tolerance (17), so this should not limit recruitment.\n\nExclusion Criteria:\n\n* Use of insulin or other anti-diabetes medications other than metformin.\n* Contraindication to taking a DPP4 inhibitor or SGLT2 inhibitor including: allergy, history of angioedema, pancreatitis, active gallbladder disease, renal impairment with EGFR \\< 45).\n* Bleeding disorder, use of anticoagulants, thrombocytopenia, or severe anemia.\n* Use of high dose steroids.\n* Current systemic chemotherapy.\n* Pregnancy or breastfeeding.\n* Recent (within 30 days) or recurrent (defined as more than one in the past 12 months) urinary tract infection or yeast infection.\n* Other contraindication that would make study participation unsafe or make study related data unable to be interpreted.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "45 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Jessica Wilson, MD",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic Florida",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Zoe A Parrales, BS",
                            "role": "CONTACT",
                            "phone": "904-953-3381",
                            "email": "parrales.zoe@mayo.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Fighting Parkinson's Disease and Lewy Body Dementia with Anti-Diabetic Medications",
                    "url": "https://www.mayo.edu/research/clinical-trials/cls-20563911"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010300",
                    "term": "Parkinson Disease"
                },
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000020961",
                    "term": "Lewy Body Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020734",
                    "term": "Parkinsonian Disorders"
                },
                {
                    "id": "D000001480",
                    "term": "Basal Ganglia Diseases"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009069",
                    "term": "Movement Disorders"
                },
                {
                    "id": "D000080874",
                    "term": "Synucleinopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13213",
                    "name": "Parkinson Disease",
                    "asFound": "Parkinson's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "asFound": "Dementia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22693",
                    "name": "Lewy Body Disease",
                    "asFound": "Lewy Body Dementia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22494",
                    "name": "Parkinsonian Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M25603",
                    "name": "Ganglion Cysts",
                    "relevance": "LOW"
                },
                {
                    "id": "M16358",
                    "name": "Synovial Cyst",
                    "relevance": "LOW"
                },
                {
                    "id": "M4774",
                    "name": "Basal Ganglia Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12029",
                    "name": "Movement Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M2217",
                    "name": "Synucleinopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000529054",
                    "term": "Dapagliflozin"
                },
                {
                    "id": "D000077203",
                    "term": "Sodium-Glucose Transporter 2 Inhibitors"
                },
                {
                    "id": "D000068900",
                    "term": "Sitagliptin Phosphate"
                },
                {
                    "id": "D000054873",
                    "term": "Dipeptidyl-Peptidase IV Inhibitors"
                }
            ],
            "ancestors": [
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000054795",
                    "term": "Incretins"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000011480",
                    "term": "Protease Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1691",
                    "name": "Sodium-Glucose Transporter 2 Inhibitors",
                    "asFound": "HIV-positive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M335",
                    "name": "Sitagliptin Phosphate",
                    "asFound": "Focus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M348449",
                    "name": "Dapagliflozin",
                    "asFound": "10 minutes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27957",
                    "name": "Dipeptidyl-Peptidase IV Inhibitors",
                    "asFound": "Watts",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27905",
                    "name": "Incretins",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M19609",
                    "name": "HIV Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M14343",
                    "name": "Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}